DOCSLIB.ORG

Biopharma Leaders Join Trump and Thunberg in Davos

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biopharma Leaders Join Trump and Thunberg in Davos No. 3989 January 31, 2020 again a key theme at Davos, and many biopharma executives are joining the con- versation this year. These include Werner Baumann, CEO of Bayer, who spoke on a panel on 21 Janu- ary about ‘When Humankind Overrides Evolution,’ focusing on gene-editing tech- nologies for use in agriculture, food and medicine. Meanwhile Takeda CEO Chris- tophe Weber joins a discussion on shap- ing the future of health and healthcare systems on 22 January. Speaking on the gene-editing panel, Baumann said there was “less and less trust in society for the advances of tech- nology,” adding that “the only way to get beyond it is that we do a better job in terms of explaining what we are doing.” Bayer is working with CRISPR Thera- peutics on CRISPR/Cas9 gene-editing in hemophilia, ophthalmology and autoim- Biopharma Leaders Join Trump mune diseases, but also has a major stake in genetically modified seeds via its Mon- And Thunberg In Davos santo division. He called for absolute transparency ANDREW MCCONAGHIE [email protected] from corporations and governments on gene-editing technology, but also decried fter focusing on the year ahead tive to plant 1 trillion trees, an effort aimed the previous “insane dominance” that anti- in biopharma business at the J.P. at soaking up rising levels of carbon diox- GM crop campaigners have been allowed AMorgan conference in San Fran- ide in the atmosphere. to wield. cisco last week, the sector’s attention has 17-year-old environmental campaigner Others taking part include Stéphane switched to the World Economic Forum in Greta Thunberg made her own address to Bancel, Moderna Therapeutics’ chief exec- Davos, Switzerland from 21-24 January. the meeting shortly afterwards, and berat- utive, and Julie Gerberding, EVP and chief The annual “big picture” summit brings ed world leaders for a lack of action, and patient officer for MSD, who will be on a together politicians, economists, academ- said planting trees was not enough. panel looking at breakthroughs in can- ics and business leaders, and this year She called on corporations, banks and cer care on 24 January, while Lars Rebien has been kicked off with a typically pro- governments to halt fossil fuel investment Sørensen, chairman of the Novo Nordisk vocative address by US President Don- and extraction. “Planting trees is good, Foundation, chaired a debate on one of ald Trump, who contradicted growing of course, but it’s nowhere near enough,” the biggest risks to future healthcare, anti- concern about climate change, decrying Thunberg said. “We don’t need to lower microbial resistance (AMR), on 21 January. what he called the “prophets of doom” on emissions….Emissions need to stop.” (Also see “Novo Executive Calls For ‘Real AMR global warming. Action’ In Davos “ - Scrip, 20 Jan, 2020.) Trump is withdrawing the US from the BIOPHARMA’S BIG THINKERS Novartis’s chief executive Vas Nara- Kyoto climate agreement, but neverthe- The future of healthcare, and the role of simhan will join a panel hosted by Fast less did pledge to join a new global initia- business and new technologies are once CONTINUED ON PAGE 4 FOR THE LATEST BUSINESS INSIGHT ON THE BIOPHARMA INDUSTRY VISIT: SCRIP.PHARMAINTELLIGENCE.INFORMA.COM UK Biotech Sector J&J’s Gorsky On Immunologicals Stockwatch Financing holds up despite Q4 results season gets underway Coronavirus and earnings Brexit and Woodford (p5) with J&J pushing immunology (p8) under scrutiny (p21) IN THIS ISSUE from the editor [email protected] Last week, Johnson & Johnson fulfilled its time-hon- depression, Spravato, which was approved in the US in ored duty of kicking off the annual financial results March then the EU in December. Hailed as an impor- reporting season, as we report on p8. The company has tant new product, its cost and complexity of adminis- managed to shore up its all-important immunology tration may be hampering its uptake. franchise against biosimilar erosion: while sales of its The US Institute for Clinical and Economic Review one-time mainstay blockbuster Remicade slipped 17% (ICER) questioned its long-term benefits and risks and in the third full year since the US launch of a biosimi- calculated that its $32,400 US list price offered “low lar, it succeeded in growing its overall immune drug value for money” and should be discounted by 25-52%. portfolio. Partly this was down to impressive growth It also warned that even with the called-for price reduc- outside the US, but even US sales grew, thanks to J&J’s tion, treating more than 20-30% of eligible patients success in launching and expanding the indications would have budgetary impacts that could displace for newer products in a highly competitive field. On- other needed services or push up insurance costs. Over cology, which is driving much of the biopharma in- in Europe, Spravato has just been knocked back for re- dustry, also served the group well. imbursement in England in draft guidance from NICE. But there was little detail on the launch performance For more on this, check out online coverage in Scrip and of the esketamine nasal spray for treatment-resistant sister publication Pink Sheet. LEADERSHIP ADVERTISING DESIGN Phil Jarvis, Mike Ward, Christopher Keeling Paul Wilkinson Karen Coleman HEAD OF SUBSCRIPTIONS PUBLICATION DESIGN Dan Simmons, Gayle Rembold Furbert Shinbo Hidenaga EDITORS IN CHIEF Andrea Charles EDITORIAL OFFICE Ian Haydock (Asia) John Davis Blue Fin Building Eleanor Malone (Europe) Kevin Grogan 3rd Floor, 110 Southwark St Denise Peterson (US) Andrew McConaghie London, SE1 0TA Ian Schofield CUSTOMER SERVICES EXECUTIVE EDITORS Vibha Sharma US Toll-Free: +1 888 670 8900 COMMERCIAL Sten Stovall Alexandra Shimmings (Europe) US Toll: +1 908 547 2200 UK & Europe: +44 (20) 337 73737 Mary Jo Laffler (US) US Australia: +61 2 8705 6907 POLICY AND REGULATORY Michael Cipriano Japan: +81 3 6273 4260 Maureen Kenny (Europe) Derrick Gingery Email: clientservices@ Nielsen Hobbs (US) Joseph Haas pharma.informa.com Mandy Jackson ASIA Cathy Kelly Anju Ghangurde Jessica Merrill TO SUBSCRIBE, VISIT scrip.pharmaintelligence.informa.com Vibha Ravi Leah Samuel Jung Won Shin Brenda Sandburg TO ADVERTISE, CONTACT Brian Yang Bridget Silverman [email protected] Sue Sutter EUROPE All stock images in this publication Neena Brizmohun courtesy of www.shutterstock.com Francesca Bruce unless otherwise stated Scrip is published by Informa UK Limited. ©Informa UK Ltd 2020: All rights reserved. ISSN 0143 7690. 2 | Scrip | January 31, 2020 © Informa UK Ltd 2020 Amgen’s JV Buy Out AZ’s Dobber On AZ And Lokelma Plans Clovis Prostate Cancer Race 20 6 10 16 exclusive online content inside: COVER / Biopharma Leaders Join Trump And Thunberg In Davos Market Snapshot: Migraine Prevention Therapies’ Slow Road To Blockbuster Status 4 Novo Executive Calls For ‘Real AMR Action’ In Davos MANDY JACKSON [email protected] 5 UK Biotech Financing Holds Up Despite Woodford and Brexit 6 Amgen To Buy Out Japan JV With Astellas 7 Piramal Profits As It Sheds DRG To Clarivate For $950m 8 J&J’s Gorsky Hails Strong Performance By Immunology Therapies Tremfya, Stelara 10 AstraZeneca’s Dobber On Ramping In Renal, Expanding In CV And Business Development 12 Roche Gears Up For Potential Neuroscience Breakthroughs The launches in 2018 of three closely watched calcitonin gene-related peptide (CGRP) inhibitors as preventive ther- 13 New CEO Brett Monia Takes The Lead As Ionis Prioritizes apies and the anticipated launches of three more products Non-Partnered Programs against the same target have brought new attention to mi- graine decades after the launch of triptans – the last big class of drugs to treat the disease’s debilitating headaches 16 Horizon Sees Blockbuster Future For Tepezza After and other symptoms. But while the migraine market is US Approval large, the first round of CGRP inhibitors have yet to achieve blockbuster status. 16 AZ’s Lynparza Gets Prostate Cancer Priority Review Amgen Inc./Novartis AG’s Aimovig (erenumab) targets the CGRP receptor while Eli Lilly & Co.’s Emgality (galcan- 17 Genentech’s SMA Type 1 Data Strengthen Case Backing ezumab) and Teva Pharmaceutical Industries Ltd.’s Ajovy Risdiplam Approval (fremanezumab) both target the CGRP ligand; all three are approved to prevent headaches in patients diagnosed 20 Health Sector On High Alert As Wuhan Coronavirus Spreads with chronic migraines (15 or more headaches per month) and episodic migraines (14 or less). The drug makers es- 21 Stockwatch: Earnings Season Catches An Early Cold timated that 6 million people in the US alone are eligible As Coronavirus Sweeps In for preventive treatment with one of these new biologics. Aimovig, Emgality and Ajovy have shown similar efficacy 22 Pipeline Watch in clinical trials, cutting the number of headache days that many migraine patients experienced by half or more. And since doctors have seen many people respond well to these 23 Appointments treatments in the real world, it would seem that growth is guaranteed given the need for new medicines in this space. Published online 23 January 2020 @PharmaScrip /scripintelligence To read the rest of this story go to: https://bit.ly/3aN0UcT /scripintelligence /scripintelligence scrip.pharmaintelligence.informa.com January 31, 2020 | Scrip | 3 HEADLINE NEWS/DAVOS MEETING CONTINUED FROM PAGE 1 Company to explore the role of CEO as Novo Executive Calls For “disruptor in chief,” something he has been pursuing with the “Unbossed” cul- tural shift in the company. ‘Real AMR Action’ In Davos The conference is not simply focused STEN STOVALL [email protected] on political and corporate leaders making well-intentioned statements on trade and ime is fast slipping away for finding workable solutions to address antimicrobial global co-operation, however. resistance, and the World Economic Forum’s annual meeting this week offers a rare Two years ago President Trump met T opportunity to spur action, says Lars Rebien Sørensen, chairman of the Novo Nor- Bayer’s Baumann and Novartis’s Narasim- disk Foundation.
Load more

Recommended publications
  • Objectives & Accreditation
    Objectives & Accreditation ACTIVITY FORMAT Live TARGET AUDIENCE This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management. TYPE OF ACTIVITY Live Activity; Application/ Knowledge EDUCATIONAL OBJECTIVES At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide appropriate care and counsel for patients and their families. At the conclusion of this activity, all participants should be able to: Session I: The Impact of Genetics in Lipidology? Apply insight from human population genetics studies to identify novel therapeutic targets for a better understanding for atherosclerotic cardiovascular disease. Describe the current and future technologies available for genetic screen includinghow to apply them in clinical practice both for diagnosis and risk assessment Discuss experimental techniques in development for genetic manipulation to target inherited lipid disorders Keynote I Discuss ApoC3 as both a risk factor for ASCVD and as potential for therapeutic manipulation Session II- Focus on Lipoprotein (a) Discuss the epidemiology of Lipoprotein(a) (LP(a)) for both thrombosis and ASCVD Discuss the pathophysiology of LP(a) and how this impacts increased risk of ASCVD and thrombosis Discuss the status of current and emerging treatment options targeting LP(a) Clinical Lipidology Track- Critically appraise emerging research
    [Show full text]
  • Pioneering New Markets Changing the Standard of Care
    ANNUAL 2020 REPORT Pioneering New Markets Changing the Standard of Care UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 2855 Gazelle Court, Carlsbad, CA 92010 (Address of Principal Executive Offices) (Zip Code) 760-931-9200 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol Name of each exchange on which registered Common Stock, $.001 Par Value ‘‘IONS’’ The Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No □ Indicate by check if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes □ No ☒ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Q1 Pharma Sector Snapshot
    SPECIALTY & GENERIC PHARMA Q1 2021 Report Market Commentary – Debt Capital Markets Debt Markets ▪ 2020 saw increased amounts of debt used in buyouts across the board, resulting in the highest debt / EBITDA Median US Buyout Multiples levels since 2014 − The increased use of debt was driven by 2H20 back- end loaded lending activity (primarily 4Q20) as 16.0x 12.7x 14.1x 12.2x 12.0x 11.6x 11.5x certainty around the U.S. election and vaccination 11.1x 10.0x 9.8x 12.0x 9.7x expectations increased 9.4x 8.6x 8.3x 8.2x 7.5x 7.8x 5.2x 6.7x 5.7x 5.6x ▪ 8.0x 5.9x As the effects of COVID now begin to diminish, debt 5.4x 4.4x 4.1x 3.7x 4.6x 4.3x 3.8x markets have seemingly recovered, signaling that 3.6x lenders have become increasingly comfortable with 4.0x 4.3x 6.9x 6.5x 6.3x 6.0x 5.9x 5.7x 5.7x 5.7x 5.7x 5.6x 5.3x 4.5x 4.4x macroeconomic and company-specific fundamentals 4.3x 0.0x 3.2x − With increased confidence, lenders are currently looking to provide strong leverage for high-quality assets, particularly ones that have proven their Debt/EBITDA Equity/EBITDA EV/EBITDA stability through the recent market downturn Source: PitchBook ▪ The spread on U.S. high-yield debt has returned to pre- Historical US High Yield Debt Effective Yield COVID levels − 4.22% current effective yield compared with a 12.0% 11.4% 11.38% effective yield on March 23, 2020 (peak of the pandemic) 9.0% ▪ We expect increased activity by lenders in 2021 due to: 6.0% 4.2% − Pent-up demand in M&A activity driven by the impact of COVID 3.0% − Limited Partner agreements and investor
    [Show full text]
  • ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021
    ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021 Company Ticker CUSIP Shares Market Value($) Weight(%) 1 TELADOC HEALTH INC TDOC 87918A105 3,937,797 531,208,815.30 6.99 2 EXACT SCIENCES CORP EXAS 30063P105 3,971,013 381,296,668.26 5.01 3 PACIFIC BIOSCIENCES OF CALIF PACB 69404D108 13,696,148 350,347,465.84 4.61 4 VERTEX PHARMACEUTICALS INC VRTX 92532F100 1,722,281 316,228,014.41 4.16 5 FATE THERAPEUTICS INC FATE 31189P102 4,825,395 312,926,865.75 4.12 6 IONIS PHARMACEUTICALS INC IONS 462222100 8,572,965 310,341,333.00 4.08 7 REGENERON PHARMACEUTICALS REGN 75886F107 430,742 275,201,063.80 3.62 8 TWIST BIOSCIENCE CORP TWST 90184D100 2,237,350 250,829,308.50 3.30 9 TAKEDA PHARMACEUTIC-SP ADR TAK UN 874060205 13,592,076 229,570,163.64 3.02 10 ACCOLADE INC ACCD 00437E102 5,268,242 226,850,500.52 2.98 11 INTELLIA THERAPEUTICS INC NTLA 45826J105 1,508,421 224,965,907.94 2.96 12 VEEVA SYSTEMS INC-CLASS A VEEV 922475108 741,198 222,307,516.14 2.92 13 CAREDX INC CDNA 14167L103 3,433,475 220,978,451.00 2.91 14 CRISPR THERAPEUTICS AG CRSP H17182108 1,804,041 210,044,493.63 2.76 15 INCYTE CORP INCY 45337C102 2,893,385 199,643,565.00 2.63 16 INVITAE CORP NVTA 46185L103 6,059,066 182,135,523.96 2.40 17 ADAPTIVE BIOTECHNOLOGIES ADPT 00650F109 4,888,391 178,377,387.59 2.35 18 BEAM THERAPEUTICS INC BEAM 07373V105 1,849,698 175,110,909.66 2.30 19 SIGNIFY HEALTH INC -CLASS A SGFY 82671G100 8,107,683 160,937,507.55 2.12 20 UIPATH INC - CLASS A PATH 90364P105 2,955,628 155,761,595.60 2.05 21 CASTLE BIOSCIENCES INC CSTL 14843C105 2,130,211
    [Show full text]
  • Fidelity® Select Portfolio® Pharmaceuticals Portfolio
    Quarterly Holdings Report for Fidelity® Select Portfolio® Pharmaceuticals Portfolio November 30, 2020 PHR-QTLY-0121 1.810707.116 Schedule of Investments November 30, 2020 (Unaudited) Showing Percentage of Net Assets Common Stocks – 98.3% Shares Value Shares Value Biotechnology – 17.6% Bausch Health Cos., Inc. (Canada) (a) 535,300 $ 9,937,694 Biotechnology – 17.6% Bristol‑Myers Squibb Co. 1,295,680 80,850,432 Acceleron Pharma, Inc. (a) 128,800 $ 15,207,416 Catalent, Inc. (a) 75,400 7,248,956 Amgen, Inc. 137,400 30,508,296 Elanco Animal Health, Inc. (a) 172,400 5,273,716 Argenx SE (a) 17,400 4,983,924 Eli Lilly & Co. 416,961 60,730,370 Ascendis Pharma A/S sponsored ADR (a) 51,300 8,655,849 GlaxoSmithKline PLC sponsored ADR 348,300 12,813,957 Atea Pharmaceuticals, Inc. 39,800 1,326,136 Harmony Biosciences Holdings, Inc. 133,077 5,467,801 Athenex, Inc. (a) (b) 166,800 2,273,484 Horizon Therapeutics PLC (a) 316,100 22,262,923 BioNTech SE ADR (a) (b) 50,148 6,230,388 Intra‑Cellular Therapies, Inc. (a) 107,000 2,529,480 Blueprint Medicines Corp. (a) 80,300 8,678,824 Johnson & Johnson 337,850 48,880,138 ChemoCentryx, Inc. (a) 6,400 352,960 Merck & Co., Inc. 515,936 41,476,095 Galapagos Genomics NV sponsored ADR (a) 36,900 4,524,309 Nektar Therapeutics (a) (b) 368,233 6,035,339 Generation Bio Co. (b) 16,738 807,106 Novartis AG sponsored ADR 441,496 40,101,082 Generation Bio Co.
    [Show full text]
  • October 2019
    J.P. Morgan Healthcare Conference Presented by Brett P. Monia, Ph.D. Chief Executive Officer January 15, 2020 Forward Looking Language Statement This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of SPINRAZA® (nusinersen), TEGSEDI™ (inotersen), WAYLIVRA™ (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' majority owned affiliate. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2018, and its most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of this and other documents are available at www.ionispharma.com. In this presentation, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and its subsidiaries.
    [Show full text]
  • *Attending Companies (As of 1.29.19) 3E Therapeutics CLINICAL
    *Attending Companies (As of 1.29.19) 3E Therapeutics CLINICAL NETWORK SERVICES 5AM Ventures CoSec Consulting AbbVie Daiichi-Sankyo Adastra Pharmaceuticals DCLSA ADYA Decoy Biosystems Alcami Corporation Deloitte Consulting, LLP Algomedix DNA Ink AlivaMab Discovery Services Donnelley Financial Solutions Allergan Drug Delivery Experts Amgen EcoR1 Capital, LLC Amgen EnduRx Pharmaceuticals Inc. Aristea Therapeutics Entos Pharmaceuticals Arivale EPL Archives LLC Aspect Biosystems Ltd Equillium Astellas Venture Management Esperion Axcelead Drug Discovery Partners FERRER INTERNACIONAL, SA Bay City Capital Forge Therapeutics Bayer FreeMind BCN Biosciences Gemseki Inc. Beacon Discovery, Inc. Genentech Boehringer Ingelheim GigaGen Boehringer Ingelheim GigaMune BriOri BioTech Gilead Sciences Bristol-Myers Squibb Global Source Ventures Calibr Glysantis Inc. CeleCor Therapeutics Gossamer Bio Cell Care Therapeutics Halloran Consulting Group Cellgen Diagnostics Halozyme Therapeutics CILcare Hamamatsu Pharma Research USA, Inc. Cipla Technologies LLC Illumina Ventures Illumina, Inc. OrPro Therapeutics, Inc. Immune Biosolutions Otonomy Inevitable Ventures Otsuka America Pharmaceuticals Ionis Pharmaceuticals Pattern Pharma Japan Bioindustry Association Pfenex JCR USA, Inc. Phoenix Molecular Designs Kalgene Pisces Therapeutics Illumina, Inc. Pivotal bioVenture Partners Immune Biosolutions Prevencio, Inc. Inevitable Ventures PrimeVax Immuno-Oncology, Inc. Ionis Pharmaceuticals Qpex Biopharma Japan Bioindustry Association Recordati Rare Disease JCR USA, Inc.
    [Show full text]
  • 12/31/20 at 0.06% Due 01/04/21 $ 969,572 969,572 Barclays Capital, Inc
    Biotechnology Fund SCHEDULE OF INVESTMENTS (Unaudited) December 31, 2020 Shares Value COMMON STOCKS† - 99.6% Biotechnology - 72.9% Amgen, Inc. 46,124 $ 10,604,830 Gilead Sciences, Inc. 137,327 8,000,671 Vertex Pharmaceuticals, Inc.* 30,030 7,097,290 Illumina, Inc.* 18,293 6,768,410 Regeneron Pharmaceuticals, Inc.* 13,496 6,520,053 Biogen, Inc.* 22,700 5,558,322 Moderna, Inc.* 49,814 5,204,069 Corteva, Inc. 125,161 4,846,234 Alexion Pharmaceuticals, Inc.* 30,030 4,691,887 Seagen, Inc.* 26,529 4,646,289 Exact Sciences Corp.* 31,204 4,134,218 Incyte Corp.* 44,634 3,882,265 Bio-Rad Laboratories, Inc. — Class A* 6,450 3,759,963 BioMarin Pharmaceutical, Inc.* 38,909 3,411,930 Alnylam Pharmaceuticals, Inc.* 25,838 3,358,165 Guardant Health, Inc.* 25,656 3,306,545 Mirati Therapeutics, Inc.* 13,253 2,910,889 Ionis Pharmaceuticals, Inc.* 48,279 2,729,695 ACADIA Pharmaceuticals, Inc.* 49,103 2,625,046 CRISPR Therapeutics AG* 16,740 2,563,061 BeiGene Ltd. ADR* 9,710 2,508,967 Acceleron Pharma, Inc.* 18,632 2,383,778 Iovance Biotherapeutics, Inc.* 50,194 2,329,002 Arrowhead Pharmaceuticals, Inc.* 30,137 2,312,412 United Therapeutics Corp.* 15,148 2,299,315 BioNTech SE ADR*,1 27,800 2,266,256 Ultragenyx Pharmaceutical, Inc.* 16,339 2,261,808 Twist Bioscience Corp.* 15,850 2,239,446 Exelixis, Inc.* 111,104 2,229,857 Novavax, Inc.*,1 19,860 2,214,589 Amicus Therapeutics, Inc.* 95,070 2,195,166 Halozyme Therapeutics, Inc.* 50,560 2,159,418 Blueprint Medicines Corp.* 18,770 2,105,056 Fate Therapeutics, Inc.* 23,040 2,095,027 Sage Therapeutics, Inc.* 23,286 2,014,472 Biohaven Pharmaceutical Holding Company Ltd.* 22,920 1,964,473 Arena Pharmaceuticals, Inc.* 25,260 1,940,726 ChemoCentryx, Inc.* 30,270 1,874,318 PTC Therapeutics, Inc.* 29,928 1,826,506 Emergent BioSolutions, Inc.* 20,360 1,824,256 Bluebird Bio, Inc.* 36,415 1,575,677 Global Blood Therapeutics, Inc.* 34,845 1,509,137 Inovio Pharmaceuticals, Inc.*,1 125,840 1,113,684 Total Biotechnology 143,863,178 Pharmaceuticals - 17.5% AbbVie, Inc.
    [Show full text]
  • Customer Margins for Onechicago Futures
    #XXXXX TO: ALL CLEARING MEMBERS DATE: August 13, 2018 SUBJECT: Customer Margins for OneChicago Futures On a monthly basis OCC updates OneChicago scan ranges used in the OCX SPAN parameter file. The frequency of the updates is intended to keep the futures customer margin rates more closely aligned with clearing margins, while maintaining regulatory minimums related to security futures. This month’s new rates will be effective on Tuesday 8/21. To receive email notification of these rate changes, which includes an attached file of the rate changes, please subscribe to the ONE Updates list from the OFRA webpage: https://www.theocc.com/risk- management/ofra/ The following scan ranges will be updated and all others will not change: Commodity Name Current Scan Code Scan Range Range Effective 8/21/2018 AAN Aarons Inc 23.0 24.2 AAP ADVANCED AUTO PARTS INCCOM 22.0 24.9 AAXN Axon Enterprise, Inc. 25.2 32.8 ABBV Abbvie Inc. 21.4 20.0 ABC AMERISOURCEBERGEN CORP 20.0 22.5 ABX BARRICK GOLD CORP 20.0 24.3 ACAD ACADIA PHARMACEUTICALS 31.5 42.1 ACH ALUMINUM CORP CHINA LTDSPON ADR H SHS 21.1 24.0 AEGN Aegion Corp 22.0 25.2 AEM Agnico Eagle Mines Limited 20.0 21.1 AEO AMERICAN EAGLE OUTFITTERS NECOM 20.0 21.2 AFSI AMTRUST FINANCIAL SERVICES ICOM 30.2 35.1 AGIO AGIOS PHARMACEUTICALS INCCOM 30.7 33.7 AGX ARGAN INCCOM 27.3 35.7 AKAM AKAMAI TECHNOLOGIES INCCOM 20.0 22.1 AKRX AKORN INCCOM 38.2 40.7 AKS AK STL HLDG CORP 34.3 38.0 ALKS Alkermes plc 27.4 39.1 ALNY ALNYLAM PHARMACEUTICALS INCCOM 46.5 54.1 ALXN ALEXION PHARMACEUTICALS INC 21.1 22.8 AMAG AMAG Pharmaceuticals Inc 34.4 43.6 AMBA AMBARELLA INCSHS 27.7 32.5 AMD ADVANCED MICRO DEVICES INC 31.7 34.5 AMED AMEDISYS INCCOM 21.9 24.2 AMN AMN HEALTHCARE SERVICES INCCOM 23.2 26.1 AMWD AMERICAN WOODMARK CORPCOM 40.4 26.9 ANET ARISTA NETWORKS INCCOM 24.7 28.3 ANF ABERCROMBIE & FITCH CO 34.8 38.9 AOBC American Outdoor Brands Corporation 22.7 24.6 APEI AMERICAN PUBLIC EDUCATION INCOM 37.0 40.8 APOG APOGEE ENTERPRISES INCCOM 20.0 23.0 ARCO ARCOS DORADOS HOLDINGS INC 22.4 24.4 ATGE Adtalem Global Education Inc.
    [Show full text]
  • Horizon Pharma Plc 2018 Irish Statutory Accounts
    Horizon Pharma plc 2018 Irish Statutory Accounts (“Irish Annual Report”) CONTENTS Page DIRECTORS AND OTHER INFORMATION 2 DIRECTORS' REPORT 3 – 69 INDEPENDENT AUDITOR’S REPORT 70 – 75 CONSOLIDATED PROFIT AND LOSS ACCOUNT 76 CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS 77 CONSOLIDATED BALANCE SHEET 78 – 79 CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY 80 CONSOLIDATED STATEMENT OF CASH FLOWS 81 – 82 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS 83 – 142 PARENT COMPANY FINANCIAL STATEMENTS 143 – 153 DIRECTORS AND OTHER INFORMATION Board of Directors at December 31, 2018 Timothy P. Walbert Michael Grey William F. Daniel Jeff Himawan, Ph.D. Ronald Pauli Gino Santini James Shannon, M.D. H. Thomas Watkins Pascale Witz Secretary and Registered Office Anne-Marie Dempsey Connaught House 1st Floor 1 Burlington Road Dublin 4 D04 C5Y6 Ireland Registered Number: 507678 Auditor PricewaterhouseCoopers Chartered Accountants and Statutory Audit Firm One Spencer Dock North Wall Quay Dublin 1 D01 X9R7 Ireland Solicitor Matheson 70 Sir John Rogerson’s Quay Grand Canal Dock Dublin 2 D02 R296 Ireland 2 DIRECTORS’ REPORT The directors present their report and the audited financial statements of the Company (as defined below) for the financial year ended December 31, 2018. Basis of Presentation The Company is a public limited company formed under the laws of Ireland. The Company operates through a number of international and U.S. subsidiaries with principal business purposes to either perform research and development or manufacturing operations, serve as distributors
    [Show full text]
  • Speakers' Portal ADPD17 CME Disclosure Form Results
    Speakers' Portal ADPD17 CME Disclosure Form Results Consulting/ Ownership/ Honoraria/ Funded Royalties/ Last Name First Name Roles Relationships Company Name Advisory Stock Options Equity Employee Other Off Label Product Use Expenses Research Patent Board Position Altstiel Larry Poster/Oral Presenter Yes Phase 2b trial data from investigative Alzheimer's vTv Therapeutics Inc. X X X disease compound currently in development Araujo Josef Invited Speaker/Faculty Yes InterVivo Solutions Inc X CRO CanCog Technologies Inc. X CRO Ashe Karen Invited Speaker/Faculty No Attems Johannes Invited Speaker/Faculty No Bateman Randall J Invited Speaker/Faculty Yes C2N Diagnostics X X X X Merck X Part of a Consortium of Pharma Pfizer X X Companies funding the DIAN-TU Trials Unit Part of a Consortium of Pharma Amgen Companies funding the DIAN-TU Trials Unit Part of a Consortium of Pharma AstraZeneca Companies funding the DIAN-TU Trials Unit Part of a Consortium of Pharma Biogen Idec X Companies funding the DIAN-TU Trials Unit Part of a Consortium of Pharma Eisai Companies funding the DIAN-TU Trials Unit Part of a Consortium of Pharma Forum Companies funding the DIAN-TU Trials Unit Bateman Randall J Invited Speaker/Faculty Yes Part of a Consortium of Pharma Janssen Pharmaceuticals Companies funding the DIAN-TU Trials Unit Part of a Consortium of Pharma Eli Lilly X Companies funding the DIAN-TU Trials Unit Part of a Consortium of Pharma Hoffmann-La Roche X Companies funding the DIAN-TU Trials Unit Part of a Consortium of Pharma Sanofi-Aventis Companies funding
    [Show full text]
  • United States Securities and Exchange Commission Washington, D.C
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33500 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1032470 (State or other jurisdiction of (I.R.S. Employer Identification incorporation or organization) No.) Fifth Floor, Waterloo Exchange Waterloo Road, Dublin 4, Ireland 011-353-1-634-7800 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on Title of each class which registered Ordinary shares, nominal The NASDAQ Stock Market value $0.0001 per share LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]